Medlab Clinical Limited (MDC.AX)

6.60 0.00 (0.00%) At close: 11:59AM AEST

Medlab Clinical Limited

Building A
Unit A5 – A6, Botany Quarter 11-13 Lord Street
Botany, NSW 2019
Australia
61 2 8188 0311
https://www.medlab.co

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sean Michael Hall	MD, CEO & Director	574.11k	N/A	1970
Mr. Kerem Kaya	CFO, COO & Company Sec.	292.83k	N/A	1973
Dr. David A. Rutolo ­ (USA), J.D., Ph.D.	Director of Science	187.44k	N/A	N/A
Mr. Ian Curtinsmith	Chief Information Officer	234.42k	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.

Corporate governance

Medlab Clinical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.